Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

Journal of Virology

Volumn 74, Issue 18, 2000, Pages 8390-8401

  Archer, R H ^a   Dykes, C ^a   Gerondelis, P ^a   Lloyd, A ^a   Fay, P ^a   Reichman, R C ^a   Bambara, R A ^a   Demeter, L M ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CELL GROWTH; DNA CLEAVAGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; POLYMERIZATION; PRIORITY JOURNAL; RNA CLEAVAGE; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

CELLS, CULTURED; DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, CALF THYMUS; VIRUS REPLICATION;

EID: 0033863784     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.18.8390-8401.2000     Document Type: Article

References (65)

1. Chimeric HIV-1 and feline immuno-deficiency virus reverse transcriptases: Critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases
2. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
3. Interaction of retroviral reverse transcriptase with template-primer duplexes during replication
4. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
5. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
6. Efficacy and safety of combination therapy with delaviridine and zidovudine: A European/Australian phase II trial
7. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase
8. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer
9. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
10. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
11. Roles of ribonuclease H in reverse transcription, p. ix and 492
12. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
13. HIV-1-specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase
14. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors
15. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients
16. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine
17. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
18. Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase
19. Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase
20. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
21. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
22. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
23. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation
24. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor
25. The efficacy and safety of delavirdine mesylate in combination with zidovudine and didanosine compared to two drug combinations of these drugs (ACTG 261)
26. Reverse transcriptase RNase H from the human immunodeficiency virus: Relationship of the DNA polymerase and RNA hydrolysis activities
27. Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase
28. Efavirenz in the management of HIV infection
29. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities
30. Truncating alpha-helix E' of p66 human immunodeficiency virus reverse transcriptase modulates RNase H function and impairs DNA strand transfer
31. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization
32. Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization
33. Human immunodeficiency virus type 1 reverse transcriptase: Spatial and temporal relationship between the polymerase and RNase H activities
34. Identification and characterization of HIV-specific RNase H by monoclonal antibody
35. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel
36. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1
37. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA
38. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene
39. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
40. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
41. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada, and Australia Study
42. Helix structure and ends of RNA/DNA hybrids direct the cleavage specificity of HIV-1 reverse transcriptase RNase H
43. Control of initiation of viral plus strand DNA synthesis by HIV reverse transcriptase
44. Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function
45. ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy
46. Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase
47. A large deletion in the connection subdomain of murine leukemia virus reverse transcriptase or replacement of the RNase H domain with Escherichia coli RNase H results in altered polymerase and RNase H activities
48. Residues in the alphaH and alphaI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer
49. Alanine-scanning mutations in the 'primer grip' of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity
50. The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity
51. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine
52. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
53. Polypurine tract primer generation and utilization by moloney murine leukemia virus reverse transcriptase
54. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: A comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val
55. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1
56. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors
57. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors
58. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor
59. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
60. Abortive reverse transcription by mutants of Moloney murine leukemia virus deficient in the reverse transcriptase-associated RNase H function
61. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity
62. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
63. Interaction of HIV-1 ribonuclease H with polypurine tract containing RNA-DNA hybrids
64. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase